Cargando…
The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
PURPOSE: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. MATERIALS AND METHODS: Asymptomatic or mildly symptomatic chemotherapy-naive men with metastatic castration-res...
Autores principales: | Kim, Choung-Soo, Theeuwes, Ad, Kwon, Dong Deuk, Choi, Young Deuk, Chung, Byung Ha, Lee, Hyun Moo, Lee, Kang Hyun, Lee, Sang Eun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Urological Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869571/ https://www.ncbi.nlm.nih.gov/pubmed/27195316 http://dx.doi.org/10.4111/icu.2016.57.3.174 |
Ejemplares similares
-
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer
por: Kim, Choung Soo, et al.
Publicado: (2017) -
Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014) -
Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting
por: Jung, Seung Il, et al.
Publicado: (2020) -
Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer—updated results
por: Kimura, Go, et al.
Publicado: (2017) -
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
por: George, Daniel J., et al.
Publicado: (2021)